NCT05129813

Brief Summary

Participants include persons receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center or buprenorphine treatment by telemedicine and Recovery Guide counseling in a church or faith-based community organization. Participants are interviewed at the outset of treatment, after 4 to 6 weeks, and then at 10 to 12 weeks of treatment. The study is an observational study aimed at evaluating the experiences and response to treatment of participants.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 15, 2021

Completed
26 days until next milestone

First Submitted

Initial submission to the registry

November 10, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 22, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2022

Completed
Last Updated

November 22, 2021

Status Verified

November 1, 2021

Enrollment Period

8 months

First QC Date

November 10, 2021

Last Update Submit

November 19, 2021

Conditions

Keywords

Opioid Use DisorderBehavioral CounselingPeer Recovery SpecialistBuprenorphine

Outcome Measures

Primary Outcomes (1)

  • Treatment Retention

    Proportion of participants continuing to receive buprenorphine treatment at 12 weeks

    12 weeks

Secondary Outcomes (2)

  • Medication adherence

    12 weeks

  • Treatment satisfaction

    12 weeks

Other Outcomes (2)

  • Self-reported opioid and other drug use

    12 weeks

  • Health-related quality of life

    12 weeks

Study Arms (2)

Buprenorphine MOUD in FQHC

Participants receiving buprenorphine treatment and Recovery Guide counseling in a Federally Qualified Health Center. Recovery Guide counseling is provided weekly.

Behavioral: Recovery Guide Counseling

Telemedicine Provision of Buprenorphine MOUD in a community site

Participants receiving buprenorphine treatment provided by telemedicine from a hub clinic and Recovery Guide counseling in a church or faith-based community organization. Recovery Guide counseling is provided weekly.

Behavioral: Recovery Guide Counseling

Interventions

Recovery Guide Counseling is a 12-session psychoeducational and behavioral counseling intended for delivery by Peer Recovery Specialists, community health workers, or other personnel without advanced training in counseling

Buprenorphine MOUD in FQHCTelemedicine Provision of Buprenorphine MOUD in a community site

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Potential participants will be recruited through posters, flyers, or word-of-mouth or information provided to them by neighborhood or community agencies or organizations or referred by their medical provider.

You may qualify if:

  • Opioid use disorder
  • Initiating buprenorphine treatment

You may not qualify if:

  • Inability to understand the study protocol or assessment questions
  • Severe medical or psychiatric co-morbidity, including active psychosis, high risk for suicide, or medical contraindications to buprenorphine (e.g., allergy or sensitivity to buprenorphine),
  • Currently (or in the past 30 days) receiving MAT for OUD.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Howard University

Washington D.C., District of Columbia, 20060, United States

RECRUITING

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Richard Schottenfeld, M.D.

    Howard University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Richard Schottenfeld, M.D.

CONTACT

Denise Scott, Ph.D.

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 10, 2021

First Posted

November 22, 2021

Study Start

October 15, 2021

Primary Completion

May 31, 2022

Study Completion

May 31, 2022

Last Updated

November 22, 2021

Record last verified: 2021-11

Data Sharing

IPD Sharing
Will not share

Locations